Arcadia Biosciences CEO Matt Plavan resigns, appoints Kevin Comcowich as interim CEO

Arcadia Biosciences, Inc.

Matt Plavan resigned as CEO, President, and board member, effective Dec 31, 2021.
Kevin Comcowich appointed interim CEO effective Jan 1, 2022; will remain board chair.
Comcowich to receive $30,833/month; Plavan severance: $61,666 on Jan 1 & Feb 1, $143,278 on Mar 1, 2022.
Plavan's stock options fully vest Dec 31, 2021, exercisable until June 30, 2024.
Related party: Company leases land from Comcowich's entity for hemp; total lease payments $240,000.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed (interim)

Kevin Comcowich

Interim Chief Executive Officer

RKDA · Arcadia Biosciences, Inc.

Effective: 2022-01-01
Filed: December 20, 2021, 6:59 PM ET

The Company has appointed Kevin Comcowich, the current chairman of the Arcadia Board of Directors, as the Company’s Interim Chief Executive Officer, effective January 1, 2022, as the board of directors finalizes its search for a permanent CEO.

Departed

Matt Plavan

Chief Executive Officer, President

RKDA · Arcadia Biosciences, Inc.

Effective: 2021-12-31
Successor: Kevin Comcowich
Filed: December 20, 2021, 6:59 PM ET

On December 14, 2021, Matt Plavan submitted his resignation from his positions as Chief Executive Officer, President and as a member of the Board of Directors (the “Board”) of Arcadia Biosciences, Inc. (the “Company” or "Arcadia"), effective December 31, 2021 (“Separation Date”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Kevin Comcowich was appointed as Interim Chief Executive Officer at Arcadia Biosciences, Inc..

Action: appointed
Role: Interim Chief Executive Officer

Exact text from the filing

The Company has appointed Kevin Comcowich, the current chairman of the Arcadia Board of Directors, as the Company’s Interim Chief Executive Officer, effective January 1, 2022, as the board of directors finalizes its search for a permanent CEO.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Matt Plavan resigned as Chief Executive Officer, President at Arcadia Biosciences, Inc..

Action: resigned
Role: Chief Executive Officer, President

Exact text from the filing

On December 14, 2021, Matt Plavan submitted his resignation from his positions as Chief Executive Officer, President and as a member of the Board of Directors (the “Board”) of Arcadia Biosciences, Inc. (the “Company” or "Arcadia"), effective December 31, 2021 (“Separation Date”).

View on SEC.gov

Arcadia Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-21-005288

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.